References
- Budman, D R. New vinca alkaloids and related compounds. Semin. Oncol. 1992, 19, 639–645. [PUBMED], [INFOTRIEVE]
- Liu, X M.; Wang, L G.; Kreis, W.; Budman, D R.; Adams, L M. Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br. J. Cancer 2001, 85, 1403–1411. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poruchynsky, M S.; Wang, E E.; Rudin, C M.; Blagosklonny, M V.; Fojo, T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998, 58, 3331–3338. [PUBMED], [INFOTRIEVE]
- Valler, M.; Green, D. Diversity screening versus focussed screening in drug discovery. Drug Discov. Today 2000, 5, 286–293. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dustin, P. Microtubules. Sci. Am. 1980, 243, 66–76. [PUBMED], [INFOTRIEVE]
- Gundersen, G G.; Cook, T. Microtubules and signal transduction. Curr. Opin. Cell Biol. 1999, 11, 81–94. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Verhey, K.; Rapoport, T. Kinesin carries the signal. Trends Biochem. Sci. 2001, 26, 545–550. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Galjart, N.; Perez, F. A plus-end raft to control microtubule dynamics and function. Curr. Opin. Cell Biol. 2003, 15, 48–53. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wubbolts, R.; Fernandez-Borja, M.; Jordens, I.; Reits, E.; Dusseljee, S.; Echeverri, C J.; Vallee, R.; Neefjes, J. Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. J. Cell. Sci. 1999, 112, 785–795. [PUBMED], [INFOTRIEVE]
- Wittmann, T.; Hyman, A.; Desai, A. The spindle: a dynamic assembly of microtubules and motors. Nat. Cell Biol. 2001, 3, E28–E34. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Downing, K.; Nogales, E. New insights into microtubule structure and function from the atomic model of tubulin. Eur. Biophys. J. 1998, 27, 431–436. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Downing, K.; Nogales, E. Tubulin and microtubule structure. Curr. Opin. Cell Biol. 1998, 10, 16–22. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zheng, Y.; Jung, M K.; Oakley, B R. Gamma-tubulin is present in Drosophila melanogaster and Homo sapiens and is associated with the centrosome. Cell 1991, 65, 817–823. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chang, P.; Stearns, T. Delta-tubulin and epsilon-tubulin: two new human centrosomal tubulins reveal new aspects of centrosome structure and function. Nat. Cell Biol. 2000, 2, 30–35. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Luduena, R F. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cyt. 1998, 178, 207–275.
- Roach, M C.; Boucher, V L.; Walss, C.; Ravdin, P M.; Luduena, R F. Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil. Cytoskelet. 1998, 39, 273–285. [CSA], [CROSSREF]
- Lewis, S A.; Gilmartin, M E.; Hall, J L.; Cowan, N J. Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J. Mol. Biol. 1985, 182, 11–20. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lewis, S A.; Cowan, N J. Complex regulation and functional versatility of mammalian alpha- and beta-tubulin isotypes during the differentiation of testis and muscle cells. J. Cell Biol. 1988, 106, 2023–2033. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gundersen, G G.; Khawaja, S.; Bulinski, J C. Postpolymerization detyrosination of alpha-tubulin: a mechanism for subcellular differentiation of microtubules. J. Cell Biol. 1987, 105, 251–264. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schulze, E.; Asai, D J.; Bulinski, J C.; Kirschner, M. Posttranslational modification and microtubule stability. J. Cell Biol. 1987, 105, 2167–2177. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chang, P.; Giddings, T J.; Winey, M.; Stearns, T. Epsilon-tubulin is required for centriole duplication and microtubule organization. Nat. Cell Biol. 2003, 5, 71–76. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168–1179. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Carre, M.; Andre, N.; Carles, G.; Borghi, H.; Brichese, L.; Briand, C.; Braguer, D. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J. Biol. Chem. 2002, 277, 33664–33669. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Blagosklonny, M V.; Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review). Int. J. Cancer 1999, 83, 151–156. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bourgarel-Ray, V.; El Khyari, S.; Rimet, O.; Guigal, N.; Braguer, D.; Seree, E.; Barra, Y.; Briand, C. Opposite effects of antimicrotubuleagents on c-myc oncogene expression depending on the cell lines used. Eur. J. Cancer 2000, 36, 1043–1049. [CROSSREF]
- Amos, L A.; Baker, T S. The three-dimensional structure of tubulin protofilaments. Nature 1979, 279, 607–612. [PUBMED], [INFOTRIEVE]
- Walker, R A.; O'Brien, E T.; Pryer, N K.; Soboeiro, M F.; Voter, W A.; Erickson, H P.; Salmon, E D. Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J. Cell Biol. 1988, 107, 1437–1448. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jordan, M A.; Farrell, K W. Differential radiolabeling of opposite microtubule ends: methodology, equilibrium exchange-flux analysis, and drug poisoning. Anal. Biochem. 1983, 130, 41–53. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Correia, J J.; Lobert, S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. 2001, 7, 1213–1228. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nogales, E. Structural insights into microtubule function. Annu. Rev. Biochem. 2000, 69, 277–302. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Penningroth, S M.; Kirschner, M W. Nucleotide binding and phosphorylation in microtubule assembly in vitro. J. Mol. Biol. 1977, 115, 643–673. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Panda, D.; Miller, H P.; Wilson, L. Determination of the size and chemical nature of the stabilizing “cap” at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002, 41, 1609–1617. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Muller-Reichert, T.; Chretien, D.; Severin, F.; Hyman, A A. Structural changes at microtubule ends accompanying GTP hydrolysis: information from a slowly hydrolyzable analogue of GTP, guanylyl (alpha,beta)methylenediphosphonate. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 3661–3666. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mitchison, T.; Kirschner, M. Dynamic instability of microtubule growth. Nature 1984, 312, 237–242. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Erickson, H P.; O'Brien, E T. Microtubule dynamic instability and GTP hydrolysis. Annu. Rev. Biophys. Biomol. Struct. 1992, 21, 145–166. [PUBMED], [INFOTRIEVE]
- Margolis, R L.; Wilson, L. Microtubule treadmilling: what goes around comes around. BioEssays 1998, 20, 830–836. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Cassimeris, L. Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr. Opin. Cell Biol. 1999, 11, 134–141. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jenkins, S M.; Johnson, G V. Microtubule/MAP-affinity regulating kinase (MARK) is activated by phenylarsine oxide in situ and phosphorylates tau within its microtubule-binding domain. J. Neurochem. 2000, 74, 1463–1468. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Poruchynsky, M S.; Giannakakou, P.; Ward, Y.; Bulinski, J C.; Telford, W G.; Robey, R W.; Fojo, T. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem. Pharmacol. 2001, 62, 1469–1480. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mistry, S.; Atweh, G. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt. Sinai J. Med. 2002, 69, 299–304. [PUBMED], [INFOTRIEVE], [CSA]
- Wood, K.; Cornwell, W.; Jackson, J. Past and future of the mitotic spindle as an oncology target. Curr. Opin. Cell Biol. 2001, 1, 370–377.
- Giodini, A.; Kallio, M J.; Wall, N R.; Gorbsky, G J.; Tognin, S.; Marchisio, P C.; Symons, M.; Altieri, D C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002, 62, 2462–2467. [PUBMED], [INFOTRIEVE]
- Alteri, D. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001, 7, 542–547. [CSA], [CROSSREF]
- Krasenti, E.; Vernos, I. The mitotic spindle: a self-made machine. Science 2001, 294, 543–547. [CROSSREF]
- Hait, W N.; Rubin, E.; Goodin, S. Tubulin targeting agents. Cancer Chemother. Biol. Response Modif. 2001, 19, 59–83. [PUBMED], [INFOTRIEVE], [CSA]
- Dustin, P. The centennial of the discovery of the antimitotic properties of colchicine. Rev. Med. Brux. 1989, 10, 385–390. [PUBMED], [INFOTRIEVE]
- Rowinsky, E K.; Donehower, R C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 1991, 52, 35–84. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lopes, N.; Miller, H.; Young, N.; Bhuyan, B. Assessment of microtubule stabilizers by semiautomated in vitro microtubule protein polymerization and mitotic block assays. Cancer Chemother. Pharmacol. 1997, 41, 37–47. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Roberge, M.; Cinel, B.; Anderson, H.; Lim, L.; Jiang, X.; Xu, L.; Bigg, C.; Kelly, M.; Anderson, R. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. Cancer Res. 2000, 60, 5052–5058. [PUBMED], [INFOTRIEVE]
- Shi, Q.; Chen, K Y.; Morris-Natschke, S.; Lee, K. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr. Pharm. Des. 1998, 4, 219–248. [PUBMED], [INFOTRIEVE], [CSA]
- Dowlati, A.; Robertson, K.; Cooney, M.; Petros, W P.; Stratford, M.; Jesberger, J.; Rafie, N.; Overmoyer, B.; Makkar, V.; Stambler, B.; Taylor, A.; Waas, J.; Lewin, J S.; McCrae, K R.; Remick, S C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62, 3408–3416. [PUBMED], [INFOTRIEVE]
- Griggs, J.; Hesketh, R.; Smith, G A.; Brindle, K M.; Metcalfe, J C.; Thomas, G A.; Williams, E D. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br. J. Cancer 2001, 84, 832–835. [PUBMED], [INFOTRIEVE]
- Blakey, D C.; Westwood, F R.; Walker, M.; Hughes, G D.; Davis, P D.; Ashton, S E.; Ryan, A J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 2002, 8, 1974–1983. [PUBMED], [INFOTRIEVE], [CSA]
- Siemann, D W.; Rojiani, A M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53, 164–171. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997, 57, 3208–3213. [PUBMED], [INFOTRIEVE]
- Yamamoto, K.; Noda, K.; Yoshimura, A.; Fukuoka, M.; Furuse, K.; Niitani, H. Phase I study of E7010. Cancer Chemother. Pharmacol. 1998, 42, 127–134. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Campbell, K.; Hersh, E.; Stopeck, A.; Glennie, K.; GA, S.; Taylor, C.; Von Hoff, D. A phase I trial of ABI-007 administered weekly for three doses every 4 weeks in patients with advanced non-hematologic malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 403a
- Rose, W C.; Fairchild, C.; Lee, F Y. Preclinical antitumor activity of two novel taxanes. Cancer Chemother. Pharmacol. 2001, 47, 97–105, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hidalgo, M.; Aylesworth, C.; Hammond, L A.; Britten, C D.; Weiss, G.; Stephenson, J., Jr.; Schwartz, G.; Patnaik, A.; Smith, L.; Molpus, K.; Felton, S.; Gupta, E.; Ferrante, K J.; Tortora, A.; Sonnichsen, D S.; Skillings, J.; Rowinsky, E K. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J. Clin. Oncol. 2001, 19, 2493–2503. [PUBMED], [INFOTRIEVE]
- Plummer, R.; Ghielmini, M.; Calvert, P.; Voi, M.; Renard, J.; Gallamt, G.; Gupta, E.; Calvert, H.; Sessa, C. Phase I and pharmacokinetic study of the new taxane analog BMS-1884476 given weekly in patients with advanced malignancies. Clin. Cancer Res. 2002, 8, 2788–2797. [PUBMED], [INFOTRIEVE], [CSA]
- Advani, R.; Fisher, G.; Lum, B L.; Jambalo, C.; Cho, C D.; Cohen, M.; Gollererki, A.; Sikic, B I. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin. Cancer Res. 2003, 9, 5187–5194. [PUBMED], [INFOTRIEVE], [CSA]
- Sullivan, D.; Dellaportas, A.; Mahany, J.; Kvols, L.; Rago, R.; Dinwoodie, W.; Lush, R.; Gallant, G.; , et al. A phase I study of BMS-188797, a novel taxane, in combination with carboplatin administered every 21 days. Clin. Cancer Res. 2001, 11 (Suppl.), 786a.
- Kadow, J.; Cook, D.; Du, K.; Hansel, S.; Johnson, W.; Mastalerz, H.; Schwartz, W.; Scola, P.; , et al. The discovery of BMS-275183, a novel, orally bioavailable taxane for human clinical evaluation. Clin. Cancer Res. 2001, 7 (Suppl.), 771a
- Rose, W C.; Long, B H.; Fairchild, C R.; Lee, F Y.; Kadow, J F. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin. Cancer Res. 2001, 7, 2016–2021. [PUBMED], [INFOTRIEVE], [CSA]
- Todd, R.; Sludden, J.; Boddy, A.; Griffin, M.; Robson, L.; Cassidy, J.; Bisset, D.; Main, M.; , et al. Phase I and pharmacological study of CT-2103, a poly (l-glutamic acid)-paclitaxel congugate. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 439a
- Shionoya, M.; Jimbo, T.; Kitagawa, M.; Soga, T.;Tohgo, A. DJ-927, novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003, 94, 459–466. [PUBMED], [INFOTRIEVE], [CSA]
- Soepenberg, O.; Sparrewboom, A.; de Jonge, M.; de Heus, G.; Paolini, J.; Angiuli, P.; Breda, M.; Bowden, C.; , et al. Phase I and pharmacologic study of a weekly schedule of LEP (liposome encapsulated paclitaxel) in patients with solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 404a
- Distefano, M.; Scambia, G.; Ferlini, C.; Gaggini, C.; De Vincenzo, R.; Riva, A.; Bombardelli, E.; Ojima, I.; Fattorossi, A.; Panici, P B.; Mancuso, S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer 1997, 72, 844–850. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ramnath, N.; Hamm, J.; Schwartz, G.; Eckhardt, G.; Bernacki, R.; Sutton, J.; Kaidbey, J.; Creaven, P. A phase I and pharmacokinetic study of a novel taxane BAY 59-8862. Clin. Cancer Res. 2001, 7 (Suppl.), 777a
- Beeram, M.; Rowinsky, E.; Hammond, L.; Patnaik, A.; Schwartz, G.; de Bono, J.; Forero, L.; Forouzesh, B.; , et al. A phase I and pharmacokinetic study of PEG-paclitaxel in patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 405a
- Sessa, C.; Cuvier, C.; Caldiera, S.; Bauer, J.; Van Den Bosch, S.; Monnerat, C.; Semiond, D.; Perard, D.; Lebecq, A.; Besenval, M.; Marty, M. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol. 2002, 13, 1140–1150. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gelmon, K A.; Latreille, J.; Tolcher, A.; Genier, L.; Fisher, B.; Forand, D.; D'Aloisio, S.; Vernillet, L.; Daigneault, L.; Lebecq, A.; Besenval, M.; Eisenhauer, E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 2000, 18, 4098–4108. [PUBMED], [INFOTRIEVE]
- Goetz, A.; Dennis, L.; Rowinsky, E.; Ochoa, L.; Molpus, K.; Deblonde, B.; Semiond, D.; Besenval, M. Phase I and pharmacokinetic study of RPR 116258A, a novel taxane derivative, administered over 1 hour every 3 weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 419a
- Spigel, S.; Jones, S.; Greco, F.; Hainsworth, J.; Dickson, N.; Willcutt, N.; Calvert, S.; Pratt, J.; , et al. S-8182 vitamin E paclitaxel emulsion: preclinical and phase I data. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 406a
- Harries, M.; O'Donnell, A.; Kaye, S.; Scurr, M.; Judson, I.; Reade, S.; Cole, C.; Twelves, C.; , et al. Phase I/II study of taxoprexin (DHA-paclitaxel) in combination with carboplatin in patients with advanced malignancies. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 2002, 400a
- Lee, F Y.; Borzilleri, R.; Fairchild, C R.; Kim, S H.; Long, B H.; Reventos-Suarez, C.; Vite, G D.; Rose, W C.; Kramer, R A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 2001, 7, 1429–1437. [PUBMED], [INFOTRIEVE], [CSA]
- LoRusso, P.; Wozniak, A.; Flaherty, L.; Shields, A.; Wright, J.; Lebwohl, D. Phase I clinical trial of BMS-247550 (aka Epothilone B Analog; NSC710428) in adult patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 215a
- Tripathi, R.; Gadgeel, S.; Wozniak, A.; Flaherty, L.; Shields, A.; Colevas, D.; Lebwohl, D.; LoRusso, P.; , et al. Phase I clinical trial of BMS-247550 (epothilone B derivative) in adult patients with advanced solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 407a
- Mekhail, T.; Holden, S.; Pierson, S.; Lee, F.; Galbraith, S M.; Cohen, M.; Messina, M.; Roedig, B.; , et al. A phase I pharmacokinetic and biologic study of the novel epothilone BMS-310705 in patients with advanced cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 408a
- Calvert, P.; O'Neill, V.; Twelves, C.; Azzabi, A.; Hughes, A.; Bales, C.; Robinson, A.; Machan, M.; , et al. A phase I clinical and pharmacokinetic study of EPO 906 (Epothilone B), given every three weeks. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2001, 20, 429a
- Kruczynski, A.; Hill, B T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol./Hematol. 2001, 40, 159–173. [CROSSREF]
- Ramnath, N.; Schwartz, G.; Booker, B.; Bong, D.; Smith, P.; Kanter, P.; Berdzik, J.; Creaven, P. A phase I and pharmacokinetic study of anhydrovinblastine. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2002, 21, 421a
- Ferrante, K.; Winograd, B.; Canetta, R. Promising new developments in cancer chemotherapy. Cancer Chemother. Pharmacol. 1999, 43, S61–S68. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rowinsky, E K.; Onetto, N.; Canetta, R M.; Arbuck, S G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 1992, 19, 646–662. [PUBMED], [INFOTRIEVE]
- Kavallaris, M.; Verrills, N M.; Hill, B T. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist. Updat. 2001, 4, 392–401. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Rao, S.; He, L.; Chakravarty, S.; Ojima, I.; Orr, G A.; Horwitz, S B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J. Biol. Chem. 1999, 274, 37990–37994. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wolff, J.; Knipling, L.; Cahnmann, H.; Palumbo, G. Direct photoaffinity labeling of tubulin with colchicine. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 2820–2824. [PUBMED], [INFOTRIEVE]
- Rai, S.; Wolff, J. Localization of the vinblastine-binding site on beta-tubulin. J. Biol. Chem. 1996, 271, 14707–14711. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chou, T C.; Zhang, X G.; Harris, C R.; Kuduk, S D.; Balog, A.; Savin, K A.; Bertino, J R.; Danishefsky, S J. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 15798–15802. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Muhlradt, P F.; Sasse, F. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity. Cancer Res. 1997, 57, 3344–3346. [PUBMED], [INFOTRIEVE]
- Altaha, R.; Fojo, T.; Reed, E.; Abraham, J. Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr. Pharm. Des. 2002, 8, 1707–1712. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Altmann, K H.; Wartmann, M.; O'Reilly, T. Epothilones and related structures—a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta 2000, 1470, M79–M91. [PUBMED], [INFOTRIEVE]
- Bollag, D M.; McQueney, P A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325–2333. [PUBMED], [INFOTRIEVE]
- Kolman, A. Epothilone D (Kosan/Roche). Curr. opin. Invest. Drugs 2004, 5, 657–667.
- Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K C.; Fojo, T. A common pharmacophore for epothilone and taxanes: molecular basisfor drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 2904–2909. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mulzer, J.; Mantoulidis, A.; Ohler, E. Total syntheses of epothilones B and D. J. Org. Chem. 2000, 65, 7456–7467. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Liu, Z Y.; Chen, Z C.; Yu, C Z.; Wang, R F.; Zhang, R Z.; Huang, C S.; Yan, Z.; Cao, D R.; Sun, J B.; Li, G. Total synthesis of epothilone A through stereospecific epoxidation of the p-methoxybenzyl ether of epothilone C. Chemistry 2002, 8, 3747–3756. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Laing, N.; Dahllof, B.; Hartley-Asp, B.; Ranganathan, S.; Tew, K D. Interaction of estramustine with tubulin isotypes. Biochemistry 1997, 36, 871–878. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Horwitz, S B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H.; Yang, C. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monographs 1993, 15, 55–61. [PUBMED], [INFOTRIEVE]
- Jordan, M A.; Wendell, K.; Gardiner, S.; Derry, W B.; Copp, H.; Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996, 56, 816–825. [PUBMED], [INFOTRIEVE]
- Wang, L G.; Liu, X M.; Kreis, W.; Budman, D R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 1999, 44, 355–361. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chaplin, D J.; Pettit, G R.; Parkins, C S.; Hill, S A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer., Suppl. 1996, 27, S86–S88. [CSA]
- Hayot, C.; Farinelle, S.; De Decker, R.; Decaestecker, C.; Darro, F.; Kiss, R.; Van Damme, M. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs with specific emphasis on the organization of the actin cytoskeleton. Int. J. Oncol. 2002, 21, 417–425. [PUBMED], [INFOTRIEVE]
- Moisoi, N.; Erent, M.; Whyte, S.; Martin, S.; Bayley, P M. Calmodulin-containing substructures of the centrosomal matrix released by microtubule perturbation. J. Cell. Sci. 2002, 115, 2367–2379. [PUBMED], [INFOTRIEVE]
- Wang, T H.; Popp, D M.; Wang, H S.; Saitoh, M.; Mural, J G.; Henley, D C.; Ichijo, H.; Wimalasena, J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 1999, 274, 8208–8216. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Glass-Marmor, L.; Beitner, R. Taxol (paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Eur. J. Pharmacol. 1999, 370, 195–199. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Giannakakou, P.; Sackett, D L.; Ward, Y.; Webster, K R.; Blagosklonny, M V.; Fojo, T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2000, 2, 709–717. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Blagosklonny, M V.; Giannakakou, P.; el-Deiry, W S.; Kingston, D G.; Higgs, P I.; Neckers, L.; Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997, 57, 130–135. [PUBMED], [INFOTRIEVE]
- Stewart, Z A.; Tang, L J.; Pietenpol, J A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 2001, 20, 113–124. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Blajeski, A L.; Phan, V A.; Kottke, T J.; Kaufmann, S H. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Invest. 2002, 110, 91–99. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Giannakakou, P.; Robey, R.; Fojo, T.; Blagosklonny, M V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001, 20, 3806–3813. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chen, J.; Horwitz, S. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 2002, 62, 1935–1938. [PUBMED], [INFOTRIEVE]
- Giannakakou, P.; Nakano, M.; Nicolaou, K C.; O'Brate, A.; Yu, J.; Blagosklonny, M V.; Greber, U F.; Fojo, T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 10855–10860. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wang, T H.; Wang, H S.; Soong, Y K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88, 2619–2628. [PUBMED], [INFOTRIEVE], [CROSSREF]
- van Oosterom, A T.; Schrijvers, D.; Schriivers, D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II. Clinical experience. Anticancer Drugs 1995, 6, 356–368. [PUBMED], [INFOTRIEVE], [CSA]
- Farshori, P Q.; Goode, D. Effects of the microtubule depolymerizing and stabilizing agents Nocodazole and taxol on glucose-induced insulin secretion from hamster islet tumor (HIT) cells. J. Submicrosc. Cytol. Pathol. 1994, 26, 137–146. [PUBMED], [INFOTRIEVE], [CSA]
- Huizing, M T.; Misser, V H.; Pieters, R C.; ten Bokkel Huinink, W W.; Veenhof, C H.; Vermorken, J B.; Pinedo, H M.; Beijnen, J H. Taxanes: a new class of antitumor agents. Cancer Investig. 1995, 13, 381–404. [CSA]
- Lobert, S.; Vulevic, B.; Correia, J J. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996, 35, 6806–6814. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chang, Y H. Mechanism of action of colchicine. I. Effect of colchicine and its analogs on the reversed passive Arthus reaction and the carrageenan-induced hindpaw edema in the rat. J. Pharmacol. Exp. Ther. 1975, 194, 154–158. [PUBMED], [INFOTRIEVE]
- Walss, C.; Kreisberg, J I.; Luduena, R F. Presence of the betaII isotype of tubulin in the nuclei of cultured mesangial cells from rat kidney. Cell Motil. Cytoskelet. 1999, 42, 274–284. [CSA], [CROSSREF]
- Xu, K.; Luduena, R. Characterization of nuclear BII-tubulin in tumor cells: a possible novel target for taxol. Cell Motil. Cytoskelet. 2002, 53, 39–52. [CSA], [CROSSREF]
- Yvon, A M.; Wadsworth, P.; Jordan, M A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 1999, 10, 947–959. [PUBMED], [INFOTRIEVE], [CSA]
- Derry, W B.; Wilson, L.; Jordan, M A. Low potency of taxol at microtubule minus ends: implicatins for its antimitotic and thewraeputic mechanism. Cancer Res. 1998, 58, 1177–1184. [PUBMED], [INFOTRIEVE]
- Snyder, J P.; Nettles, J H.; Cornett, B.; Downing, K H.; Nogales, E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 5312–5316. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- He, L.; Orr, G.; Horowitz, S. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov. Today 2001, 22, 1153–1164. [CROSSREF]
- Kar, S.; Fan, J.; Smith, M.; Goedert, M.; Amos, L. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003, 22, 70–77. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Panda, D.; Miller, H P.; Islam, K.; Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 10560–10564. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ling, Y.; Jiang, J.; Holland, J.; Perez-Soler, R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol. Pharmacol. 2002, 62, 529–538. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Dumontet, C. Mechanisms of action and resistance to tubulin-binding agents. Expert Opin. Investig. Drugs 2000, 9, 779–788. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Burkhart, C A.; Kavallaris, M.; Band Horwitz, S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta 2001, 2, O1–O9.
- Drukman, S.; Kavallaris, M. Microtubule alterations and resistance to tubulin-binding agents (Review). Int. J. Oncol. 2002, 21, 621–628. [PUBMED], [INFOTRIEVE]
- Kavallaris, M.; Kuo, D Y.; Burkhart, C A.; Regl, D L.; Norris, M D.; Haber, M.; Horwitz, S B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 1997, 100, 1282–1293., [PUBMED], [INFOTRIEVE], [CSA]
- Kavallaris, M.; Tait, A S.; Walsh, B J.; He, L.; Horwitz, S B.; Norris, M D.; Haber, M. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001, 61, 5803–5809. [PUBMED], [INFOTRIEVE]
- Kavallaris, M.; Burkhart, C A.; Horwitz, S B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer 1999, 80, 1020–1025. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goncalves, A.; Braguer, D.; Kamath, K.; Martello, L.; Briand, C.; Horwitz, S.; Wilson, L.; Jordan, M A. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 11737–11742. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zunino, F.; Cassinelli, G.; Polizzi, D.; Perego, P. Molecular mechanisms of resistance to taxanes and therapeutic implications. Drug Resist. Updat. 1999, 2, 351–357. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Giannakakou, P.; Poy, G.; Zhan, Z.; Knutsen, T.; Blagosklonny, M.; Fojo, T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000, 19, 3078–3085. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yang, H.; Horowitz, S. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther. 2001, 1, 3–10. [PUBMED], [INFOTRIEVE], [CSA]
- Bhalla, K.; Huang, Y.; Tang, C.; Self, S.; Ray, S.; Mahoney, M E.; Ponnathpur, V.; Tourkina, E.; Ibrado, A M.; Bullock, G.; , et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994, 8, 465–475. [PUBMED], [INFOTRIEVE]
- Rubenstein, S M.; Baichwal, V.; Beckmann, H.; Clark, D L.; Frankmoelle, W.; Roche, D.; Santha, E.; Schwender, S.; Thoolen, M.; Ye, Q.; Jaen, J C. Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J. Med. Chem. 2001, 44, 3599–3605. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Efferth, T.; Fabry, U.; Osieka, R. Damage of the kinesin heavy chain gene contributes to the antagonism of cisplatin and paclitaxel. Anticancer Res. 2000, 20, 3211–3219. [PUBMED], [INFOTRIEVE], [CSA]
- Goldstein, L. Kinesin molecular motors: transport pathways, receptors, and human disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 6999–7003. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wood, K.; Beraud, C.; Chabala, J.; Crompton, A.; Finer, J.; Frisch, A.; Lee, Y.; Lewis, E.; , et al. Inhibitors of the mitotic kinesin KSP: discovery and proof of principal anti-tumor activity. Proc. Am. Assoc. Cancer Res. 2002, 41, 3300a
- SC, H.; Vale, R.; Kuntz, I. Inhibitors of kinesin activity from structure-based computer screening. Biochemistry 2000, 39, 2805–2814. [CROSSREF]
- Chu, Q.; Holen, K.; Rowinsky, E.; Alberti, D.; Monroe, P.; Volkman, J.; Hodge, J.; Sabry, J.; Ho, P.; Wilding, G. A phase I study to determine the safety and pharmacokinetics of IV administrated SB-715992, a novel kinesin spindle protein inhibitorm in patients with solid tumors. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2003, 22, 525a
- Patnaik, A.; Forero, L.; Goetz, A.; Tolcher, A.; Beeram, M.; De Bono, J.; Weiss, G.; Wood, L.; Takimoto, C.; Rowinsky, E. HMN-14, a novel oral antimicrotubular agent and inhibitor of polo-like and cyclin-dependent-kinases: clinical, pharmacokinetic and pharmacodynamic relationships observed in a phase I trial of a daily X 5 schedule every 28 days. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2003, 22, 514a
- Workman, P.; Kaye, S. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 2002, 8 (Suppl.), s1–s9. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]